|
|
 |
|
Management Biographies |
|
|
 |
|
|
C. RON CHEELEY
Senior Vice President, Global Human Resources
Schering-Plough Corporation
Kenilworth, New Jersey
C. Ron Cheeley is senior vice president, Global Human Resources,
for Schering-Plough Corporation.
Cheeley joined Schering-Plough in his present position effective Aug. 1, 2003.
He is a member of Schering-Plough's Executive Management Team and Operations Management Team. He is responsible for overseeing Schering-Plough's human resources function worldwide, including providing counsel with respect to the company's organizational structure, executive succession and all major human resources policies and programs. Cheeley is also responsible for public and community affairs, administrative services, and employee health and wellness.
Before coming to Schering-Plough, Cheeley had been group vice president,
global compensation and benefits, for Pharmacia Corporation. Previously, he
served as director, global compensation and benefits, for The Coca-Cola Company.
During his career at
Coca-Cola, he also served as director of human resources for Coca-Cola India.
Cheeley holds a B.B.A. degree in accounting from the University of Georgia
and a Master of Insurance degree from Georgia State University with a concentration
in property and casualty risk management and employee benefits. He also holds a
certificate in strategic human resources management from Duke University Fuqua
School of Business.
Cheeley is a member of the Schering-Plough Foundation Board of Trustees.
He was chairman of the board of directors and a member of the executive committee
of WorldatWork from 1999-2000. He is a past member of and has served as chairman
of the Conference Board Research Council on Employee Benefits. He also has served
on the Conference Board Executive Compensation Council and currently serves as a
member of the American Benefits Council and the National Academy of Chief Human
Resources Officers. Cheeley serves on the board of directors of the Susan G. Komen
Breast Cancer Foundation.
Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.
|
|
|
 |
|
|
|
|
|
| • |
World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530 |
|
| • |
Chairman and CEO:
Fred Hassan |
|
| • |
Number of employees:
55,000 |
|
|
| • |
Net sales (2007):
$12.7 billion |
|
|
| • |
Business operations in more than:
140 countries |
|
| • |
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX. |
|
| • |
R&D investment
(2007):
$2.9 billion |
|
| • |
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health
*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
|
|
|
|
|
 |
|
About Us
